ANZCTR search results

The current project aims to: " Use principles of Implementation Science to promote uptake of, and confidence in using the Unified Protocol for Adolescents (UP-A) by CYMHS clinicians with anxious and/or depressed adolescents in the real world setting of a CYMHS community clinic. " Evaluate the UP-A compared to treatment as usual (TAU). It is hypothesised that by the end of the proposed project: " The confidence of CYMHS clinicians in the utility and delivery of the UP-A with anxious and/or depressed adolescents will have increased following a sequence of targeted implementation processes to support uptake of the EBT in community Clinic A; and " The UP-A will produce superior outcomes on measures of adolescent anxiety and depressive symptomatology compared to TAU.

Severe early-onset intrahepatic cholestasis of pregnancy (ICP), a recognised rare disease of pregnancy, is associated with increased rates of stillbirth, preterm birth and neonatal morbidity. The optimal treatment and management of women who are diagnosed with this condition are not known. We plan to compare a standard treatment used for cholestatic itch outside pregnancy (rifampicin) with a standard treatment of ICP (ursodeoxycholic acid - UDCA) to determine comparative safety and efficacy.

There is a growing body of evidence that identifies obesity as a major risk factor for a number of diseases, including Type 2 diabetes, cardiovascular disease and some cancers. In Australia, the prevalence of overweight and obesity has been increasing; 63% of adults were classed as overweight or obese in 2014-15, up from 57% in 1995. The National Health and Medical Research Council clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia identifies primary care as playing an important role in weight management. Obesity has also recently been classified as a disease by the Royal Australian College of General Practice (RACGP), and there are increasing calls for primary care to screen for overweight and obesity. Previous studies suggest few patients attending general practice in Australia are weighed, and few at risk patients are given advice or referred to other services. Identified barriers include concerns about upsetting patients and perceptions that effective interventions are lacking. Few studies have evaluated the impact of weight management interventions delivered by primary care practitioners, but there is some evidence that GP referrals to programmes outside of the primary care setting can be effective, though studies are limited. Initiating weight management conversations in primary care is therefore a controversial issue, and there is a need to explore the views of those directly affected by overweight and obesity. Community Juries are a deliberative democracy technique that involve providing a jury, made up of community members, with expert information about both sides of a controversial issue. The jury then deliberate amongst themselves, and are asked to form a consensus or majority “verdict” on the topic question, which can influence health policy decision-making. The aim of this Community Jury is to elicit the views of well-informed people with overweight and obesity about the role of GPs in initiating conversations about weight management.

This study will develop and test a new program called SHINE, and builds on a significant body of work from our successful team of international collaborators. SHINE will deliver universal education about healthy nutrition and physical activity for all adolescents. At the same time, it will dynamically tailor content to provide additional advice for the targeted/selected young people with weight and shape concerns who are at risk of developing disordered eating behaviours and attitudes. It will also provide specific guidance for those who are overweight or obese, where intervention is indicated. Using machine learning predictive models to deliver individually customised advice, SHINE provides core health messages and, where indicated, additional information to optimise intervention engagement and efficacy. The program is tailored to increase the potential to improve body image and weight-related problems; improve nutrition and physical activity; help prevent the development/progression of obesity; and thereby decrease the associated morbidities in later life. The effectiveness of SHINE will be compared with the usual health curriculum.

An amendment to the ethics committee to include people with heart failure was submitted on 28/11/2018 and approved on 17/12/2018. The aim of the study is to determine if one session of exercise on a treadmill or cycle ergometer will alter the cognitive function in people with COPD or heart failure Patients wit COPD or heart failure will be recruited from pulmonary rehabilitation and randomised via computerised randomisation generation to either the treadmill/cycle group or the quiet sitting group. Participants complete the MoCa Version 7.1 and COPD participants will be asked to walk on the treadmill for 20 minutes at 80% of the average six-minute walk test speed calculated from the better of two six-minute walk tests. Participants with heart failure will be asked to cycle on a stationary cycle ergometer for 20 minutes at 60% of their peak exercise capacity calculated from the better of two six-minute walk tests. At completion of the exercise, participants will rest until oxygen saturation, heart rate and breathlessness returns to pre exercise levels. At this point participants will be asked to complete the MoCa Version 7.2, For the quiet sitting, participants will complete the MoCa version 7.1 and then be asked to sit in a quiet room and listen to music of their choice for 20 minutes, following which they will complete MoCa version 7.2. Two version of the MoCa will be used to control for test familiarity of repeated testing.

To evaluate the ocular signs and symptoms following 2 hours of contact lens wear following soaking with 3 commercially available contact lens care multipurpose disinfectant solutions. Two types of lens materials will be used - a hydrogel lens (Etafilcon A) and silicone hydrogel lens (Comfilcon A). Both the dispensing investigators and the contact lens wearers will be masked.

The aim of this research study is to compare the efficacy and cost effectiveness of three online interventions targeting healthy eating in young Australian adults aged 18-24 years. Each group will vary in level of technology delivered personalised feedback they will receive on their dietary patterns and other support strategies offered for them to improve their diet quality and eating habits.

This is a double-blind, randomised, comparator-controlled, four (4) arm, prospective investigation. The primary objective of this clinical investigation is to identify the optimal configuration of TrimphDent required to produce a clinical outcome similar to or better than that of autologous bone graft. The secondary objective of the clinical investigation is to evaluate the safety and usability of TrimphDent.

Excess consumption of sugar-sweetened beverage (SSB) has been linked to obesity in adults. While efforts were made to reduce SSB consumption, there were concerns that this may lead to compensatory increase in consumption of other caloric nutrients, such as alcohol. This study aimed to assess the association between consumption of SSB and consumption of alcoholic beverage, as well as the effect of substituting SSB with alcoholic beverage on waist circumference.

This a multicentre phase II clinical trial to establish if low dose continuous Panobinostat is effective and safe in patients with relapsed or refractory cancer. Who is it for? You may be eligible for this study if you are less than 40 years old and have relapsed or refractory osteosarcoma, rhabdoid tumour and/or neuroblastoma. Study details All participants will receive oral Panobinostat for up to 12 months after completing their conventional therapy. Participants will have physical examinations, blood tests, urine tests, ECGs and imaging, including MRI/CT, MIBG or FDG-PET (depending on tumour type). This study will test the effectiveness of this new drug in paediatric, adolescent and young adult patients in cases where treatment options are limited.